Market cap
₹487 Cr
Revenue (TTM)
₹87 Cr
P/E Ratio
25.6
P/B Ratio
4.9
Div. Yield
0 %
| Trident Lifeline | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
487 | 21,555 | 19,802 | 18,323 | 17,490 |
Revenue (₹ Cr) |
87 | 2,287 | 1,682 | 2,570 | 3,230 |
Net Profit (₹ Cr) |
10.49 | 678.07 | 273.51 | 735.15 | 666.92 |
Net Margin (%) |
11.02 | 28.10 | 16.19 | 26.88 | 20.60 |
RoE (%) |
18.78 | 19.73 | 11.15 | 19.16 | 18.75 |
Price to Earnings |
25.60 | 32.40 | 66.60 | 24.92 | 27.16 |
Price-To-Book |
4.95 | 5.87 | 7.37 | 4.16 | 4.34 |
Income Statement (₹ Cr)
| Trident Lifeline | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Operating Revenue
|
86.96 | 1,937.47 | 1,286.43 | 2,281.35 | 2,893.64 |
|
Total Income
|
95.20 | 2,033.90 | 1,322.88 | 2,453.60 | 2,912.00 |
|
Total Expenditure
|
71.95 | 1,290.54 | 980.18 | 1,541.03 | 1,876.44 |
|
EBITDA
|
15.02 | 646.93 | 306.25 | 740.32 | 1,017.20 |
|
Depreciation
|
5.49 | 65.96 | 112.99 | 60.79 | 315.46 |
|
EBIT
|
9.52 | 580.97 | 193.26 | 679.53 | 701.74 |
|
Interest
|
4.14 | 0.61 | 75.53 | 8.50 | 231.29 |
|
Other Income
|
8.23 | 96.43 | 36.45 | 172.25 | 18.36 |
|
Exceptional Items
|
-- | -- | -30.58 | 172.81 | -- |
|
Profit before Tax
|
13.61 | 676.78 | 122.33 | 1,016.09 | 488.87 |
|
Provision for Tax
|
3.12 | 135.69 | 44.04 | 248.49 | 114.20 |
|
Profit after Tax
|
10.49 | 541.09 | 78.29 | 767.60 | 374.67 |
Liabilities (₹ Cr)
| Trident Lifeline | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
64.46 | 2,850.49 | 2,362.70 | 4,217.41 | 2,854.36 |
|
Minority Interest
|
5.19 | 35.90 | 1.04 | -- | 417.40 |
|
Non-Current Liabilities
|
30.40 | 13.24 | 259.78 | 54.89 | 2,100.97 |
|
Current Liabilities
|
55.20 | 305.99 | 674.19 | 569.51 | 1,492.79 |
|
Total Liabilities
|
157.20 | 3,207.85 | 3,310.68 | 4,911.11 | 6,865.52 |
Assets (₹ Cr)
| Trident Lifeline | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
60.60 | 1,071.67 | 2,313.20 | 1,328.96 | 5,531.13 |
|
Current Assets
|
92.02 | 2,133.95 | 984.51 | 3,512.85 | 1,334.39 |
|
Total Assets
|
157.20 | 3,207.85 | 3,310.68 | 4,911.11 | 6,865.52 |
|
Total Debt*
|
54.03 | 0.55 | 586.37 | 2.50 | 2,421.66 |
|
Net Current Assets
|
36.82 | 1,827.96 | 310.32 | 2,943.34 | -158.40 |
|
Contingent Liabilities
|
17.00 | 0.64 | 76.22 | 363.79 | 51.96 |
Cashflow (₹ Cr)
| Trident Lifeline | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-10.24 | 432.37 | 132.27 | 659.75 | 1,065.01 |
|
Cash Flow from Investing Activities
|
-13.82 | -334.73 | -199.13 | -71.34 | -79.97 |
|
Cash from Financing Activities
|
19.76 | -38.32 | 62.65 | -205.34 | -881.32 |
|
Net Cash Inflow / Outflow
|
-4.31 | 59.32 | -4.21 | 383.07 | 103.72 |
Ratios
Profitability Ratios
| Trident Lifeline | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
ROCE (%)
|
19.17 | 26.22 | 6.95 | 26.21 | 13.59 |
|
ROE (%)
|
18.78 | 21.72 | 3.75 | 19.65 | 13.81 |
|
ROA (%)
|
8.64 | 18.37 | 2.45 | 17.03 | 5.48 |
|
EBIT Margin (%)
|
26.73 | 38.37 | 26.64 | 40.00 | 35.79 |
|
Net Margin (%)
|
11.02 | 26.60 | 5.92 | 31.28 | 12.87 |
|
Cash Profit Margin (%)
|
18.38 | 31.33 | 14.87 | 34.70 | 23.21 |
Growth Ratios
| Trident Lifeline | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
94.86 | 14.37 | 11.71 | 4.02 | 44.02 |
|
EBIT Growth (%)
|
125.42 | 20.21 | 35.64 | 11.86 | 48.22 |
|
Net Profit Growth (%)
|
76.69 | 17.27 | 145.00 | 39.23 | -5.65 |
|
EPS Growth (%)
|
85.19 | 17.25 | 118.00 | 39.23 | -10.39 |
|
Book Value Growth (%)
|
23.80 | 23.77 | 30.63 | 17.30 | 10.19 |
Valuation Ratios
| Trident Lifeline | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Price / Earnings
|
25.16 | 28.38 | 41.41 | 23.86 | 54.83 |
|
Price / Book Value
|
4.78 | 5.52 | 2.74 | 4.34 | 6.78 |
|
Dividend Yield (%)
|
0.00 | 0.30 | 0.15 | 4.12 | 0.52 |
|
EV/EBITDA
|
14.93 | 19.78 | 20.55 | 17.01 | 20.75 |
|
Market Cap (₹ Cr)
|
295.53 | 15,219.80 | 6,484.12 | 18,318.10 | 19,292.77 |
Solvency Ratios
| Trident Lifeline | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.87 | 0.00 | 0.25 | 0.00 | 0.85 |
|
Short term debt to equity ratio
|
0.26 | 0.00 | 0.13 | 0.00 | 0.14 |
|
Current Ratio
|
1.67 | 6.97 | 1.46 | 6.17 | 0.89 |
|
Quick Ratio
|
1.16 | 5.88 | 0.94 | 5.33 | 0.67 |
|
Interest Coverage
|
4.29 | 1,110.48 | 2.62 | 120.54 | 3.11 |
Operating Efficiency Ratios
| Trident Lifeline | Caplin Point Lab | Shilpa Medicare | Pfizer | Eris Lifesciences | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
31.83 | 32.65 | 34.26 | 8.46 | 15.85 |
|
Asset Turnover
|
0.72 | 0.66 | 0.40 | 0.53 | 0.43 |
|
Receivable days
|
86.30 | 110.70 | 118.15 | 29.10 | 54.06 |
|
Inventory Days
|
85.68 | 65.86 | 98.29 | 69.53 | 32.16 |
|
Payable days
|
110.89 | 105.88 | 128.16 | 76.77 | 140.91 |
|
Cash Conversion Cycle
|
61.09 | 70.68 | 88.28 | 21.86 | -54.69 |